Keywords: سورفانیب; Nanoemulsion; Parenteral delivery; Anti-cancer; Sorafenib; Response Surface Methodology;
مقالات ISI سورفانیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: سورفانیب; combination therapy; cost-effectiveness analysis; hepatocellular carcinoma; monotherapy; sorafenib;
Keywords: سورفانیب; Cisplatin; Gemcitabine; Metastatic collecting duct carcinoma; Progression-free survival; Sorafenib;
Keywords: سورفانیب; Tivozanib; Sorafenib; First-line therapy; Metastatic renal cell carcinoma;
Keywords: سورفانیب; Carcinoma hepatocelular (CHC); Cirrosis; SÃndrome metabólico; Hepatitis vÃrica crónica; Trasplante hepático; Quimioembolización; Sorafenib;
Keywords: سورفانیب; AFP; alpha fetoprotein; Akt; serine/threonrine kinase; ALT; alanine aminotransferase; apoAâ
; apolipoprotein Aâ
; AST; aspartate transaminase; CPT1; carnitine palmitoyltransferase 1; FASN; fatty acid synthase; GAPDH; glyceraldehyde-3-phosphate dehydroge
Keywords: سورفانیب; Hepatocellular carcinoma; Reconstituted high density lipoprotein; Sorafenib; antimiRNA21; Anti-angiogenesis;
Keywords: سورفانیب; Drug delivery; Lipid carrier; Nanotechnology; Nanocarrier; Controlled release; NEMS; Nano electromechanical systems; MEMS; Micro-electromechanical systems; NE; Nanoemulsions; NPs; Nanoparticles; QD; Quantum dots; PLA; Polylactic acid; PGA; Polyglycolic ac
Keywords: سورفانیب; calcipotriol; hand-foot syndrome; hepatitis; hepatocellular carcinoma; sorafenib; sorafenib-associated hand-foot syndrome; treatment;
Keywords: سورفانیب; Renal cell cancer; Management; Adjuvant; Sunitinib; Sorafenib; Guidelines;
Keywords: سورفانیب; Ferroptosis; Hepatocellular carcinoma; Haloperidol; Sorafenib; ROS; reactive oxygen species; S1R; sigma 1 receptor; S1RKO; S1R-knockout; RCD; regulated cell death; CCK-8; Cell Counting Kit-8; GPX4; glutathione peroxidase 4; GSH; glutathione; NRF2; nuclear
Keywords: سورفانیب; Hepatocellular carcinoma; Personalized medicine; Sorafenib; Biomarkers; Molecular marker based-therapy; Individualized therapy; HCC; hepatocellular carcinoma; ICC; intrahepatic cholangiocarcinoma; PCNA; proliferating cell nuclear antigen; CIN; chromosomal
Keywords: سورفانیب; Hepatocellular carcinoma; Sorafenib; IFN-λ3; Proliferation; Apoptosis; Synergy;
Keywords: سورفانیب; Antineoplastic agents/adverse effects; Angiogenesis inhibitors; Cardiotoxins; Vascular endothelial growth factor; Bevacizumab; Sorafenib; Sunitinib; Vandetanib; Aflibercept;
Keywords: سورفانیب; cost-effectiveness; hepatocellular carcinoma; sorafenib; TARE;
Keywords: سورفانیب; Sorafenib; Enzalutamide; Castration-resistant prostate cancer; Androgen receptor; Tyrosine kinase; PCa; prostate cancer; CRPC; castration-resistant prostate cancer; ADT; androgen deprivation therapy; AR; androgen receptor; Enz; enzalutamide; Sor; sorafeni
Keywords: سورفانیب; Hepatocellular carcinoma; Type II diabetes mellitus; Insulin; Sorafenib; Metformin; SIRT-3; NASH; NAFLD; Liver cancer;
Keywords: سورفانیب; cabozantinib; depigmentation; dyspigmentation; hyperpigmentation; hypopigmentation; imatinib; ipilimumab; nivolumab; pazopanib; pembrolizumab; pigmentary; repigmentation; sorafenib; sunitinib; vitiligo; AE; adverse event; Bcr-abl; breakpoint cluster regio
Keywords: سورفانیب; Pazopanib; Renal cell carcinoma; Sorafenib; Sunitinib; Survival;
Keywords: سورفانیب; Pretreatment prealbumin; Prognosis; Renal cell carcinoma; Sorafenib; Sunitinib;
Keywords: سورفانیب; Liver cancer; Sorafenib; Molecular targeted therapy; Drug resistance;
Keywords: سورفانیب; Angiogenesis; Breast cancer; Bevacizumab; VEGF; Sorafenib; Sunitinib; Ramucirumab;
Keywords: سورفانیب; Graft strategy; Graft to; Poly(l-histidine); “On-off” switch; Mesoporous silica nanoparticles; Sorafenib;
Keywords: سورفانیب; ACL; Aceclofenac; AUC; area under the curve; BBB; blood-brain barrier; BCS; Biopharmaceutical classification system; BVC; bupivacaine; CNS; central nervous system; CUR; Curcumin; DMBA; 7,12-dimethylbenzanthracene; DOX; doxorubicin; DSPE-PEG2000; 1,2-diste
Keywords: سورفانیب; Hepatocarcinoma; Sorafenib; Quimioembolización; Terapia puente; Hepatocellular carcinoma; Sorafenib; Chemoembolisation; Bridge therapy;
Keywords: سورفانیب; Hepatocellular carcinoma; Liver transplantation; Ablation; Transarterial chemoembolization (TACE); Functional MRI; Sorafenib
Keywords: سورفانیب; Liver cancer; Progenitor cells; Thalidomide; Analogues; Lenalidomide; Sorafenib; Apoptosis; Mitosis; LPCs; liver progenitor cells; HCC; hepatocellular carcinoma; FDA; Federal Drug Administration; SAR; structure activity relationship; BMOL; bipotential mou
Keywords: سورفانیب; Gastric cancer; Pluronic NP; Anticancer therapy; Sorafenib; Apoptosis;
Keywords: سورفانیب; mRCC; sorafenib; sunitinib; thyroid function; TKI;
Keywords: سورفانیب; Hepatocellular carcinoma; Sarcopenia; Sorafenib; Tyrosine kinase inhibitor; Visceral fat area;
Keywords: سورفانیب; Magnetic nanoparticles; PLGA; Liver cancer; Sorafenib; Magnetic resonance imaging; Nanomedicine
Keywords: سورفانیب; Bevacizumab; Lapatinib; Sunitinib; Sorafenib; Rofecoxib; Celecoxib; Venlafaxine; Prednisone Licorice acid; cyclosporin A; Medications; Drug-induced hypertension; Blood pressure; chemicals; Tyrosine kinase inhibitors;
Keywords: سورفانیب; Acute myeloid leukemia; Azacitidine; Decitabine; Hematopoietic stem cell transplant; Maintenance therapy; Panobinostat; Sorafenib; QuizartinibAML, acute myeloid leukemia; CIBMTR, center for international blood and marrow transplant; CR, complete response;
Keywords: سورفانیب; High risk AML; FLT3; Sorafenib; Midostaurin; Quizartinib; Volasertib; IDH; CPX-351; Sapacitabine; Vosaroxin; Gemtuzumab ozogamicin; Bispecific T-cell engaging antibodies
Keywords: سورفانیب; Hepatocellular carcinoma; Systemic treatment; Drug development; Molecular targeted agents; Signalling pathway; Molecular biomarkers; Sorafenib;
Keywords: سورفانیب; hepatocellular carcinoma; rupture; sarcomatous; sorafenib
Keywords: سورفانیب; Antiangiogenic agents; Metastatic renal cells cancer; Complete response; Sunitinib; Sorafenib; Pazopanib; Bevacizumab; Cytokines; Interferon;
Keywords: سورفانیب; Hepatocellular carcinoma; Sorafenib; Radiotherapy
Keywords: سورفانیب; Resection; Ablation; Transplantation; Sorafenib; Prevention
Keywords: سورفانیب; Renal cell carcinoma; Sorafenib; Pazopanib; Everolimus; Sunitinib; Bevacizumab; Axitinib; Antiangiogenic therapy; Treatment algorithm;
Keywords: سورفانیب; renal cell carcinoma; prognosis; survival; sunitinib; sorafenib;
Keywords: سورفانیب; Sorafenib; Cyclin D1; Survivin; Non–small-cell lung cancer; STAT3
Keywords: سورفانیب; Renal cell carcinoma; Non-clear cell; Metastatic; Papillary; Chromophobe; Systemic therapy; Targeted therapy; Temsirolimus; Sunitinib; Sorafenib
Keywords: سورفانیب; Diaryl ureas; Sorafenib; Linker; Antitumor activity
Keywords: سورفانیب; Cancer; Gastrointestinal perforation; Sorafenib; Sunitinib; Vandetanib; Axitinib; Pazopanib; Cediranib; Meta-analysis;
Keywords: سورفانیب; Hepatocellular carcinoma; Transplantation; Locoregional therapy; Transarterial chemoembolization (TACE); Sorafenib;
Keywords: سورفانیب; Guanidine; Sorafenib; Protein kinases; RAF-1; MEK-1; Docking; EGFR; Epidermal growth factor receptor; ERK; extracellular signal-regulated kinase; HB; hydrogen bond; MAPK; Mitogen-activated protein kinase; MEK; Mitogen-activated protein/extracellular signa
Keywords: سورفانیب; Liver cancer; Sorafenib; Personalized medicine; Clinical trials;
Keywords: سورفانیب; Hepatocellular carcinoma; MDCT; Perfusion CT; Sorafenib;
Keywords: سورفانیب; Dynamic contrast enhanced ultrasound; Hepatocellular carcinoma; Sorafenib; Tumour response;